H.C. Wainwright lowered the firm’s price target on Karyopharm to $8 from $10 and keeps a Buy rating on the shares post the Q4 report. The analyst cites reduced Xpovio revenue estimates for the target drop.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on KPTI:
- Bad News for Karyopharm Therapeutics INC Stock: This New Risk Has Been Added
- Karyopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress
- Karyopharm Regains Compliance, Secures Nasdaq Listing
- KPTI Earnings this Week: How Will it Perform?
- Karyopharm CFO Michael Mason sell 4,205 shares
